Rivastigmine en es it fr

Rivastigmine Brand names, Rivastigmine Analogs

Rivastigmine Brand Names Mixture

  • No information avaliable

Rivastigmine Chemical_Formula


Rivastigmine RX_link


Rivastigmine fda sheet

Rivastigmine FDA

Rivastigmine msds (material safety sheet)

Rivastigmine Synthesis Reference

No information avaliable

Rivastigmine Molecular Weight

250.337 g/mol

Rivastigmine Melting Point

No information avaliable

Rivastigmine H2O Solubility

No information avaliable

Rivastigmine State


Rivastigmine LogP


Rivastigmine Dosage Forms

Capsule; Solution

Rivastigmine Indication

For the treatment of mild to moderate Alzheimer's disease.

Rivastigmine Pharmacology

Rivastigmine is a parasympathomimetic and a reversible cholinesterase inhibitor. Rivastigmine is indicated for the treatment of mild to moderate dementia of the Alzheimer's type. Pathological changes in Dementia of the Alzheimer type involve cholinergic neuronal pathways that project from the basal forebrain to the cerebral cortex and hippocampus. These pathways are thought to be intricately involved in memory, attention, learning, and other cognitive processes. While the precise mechanism of rivastigmine's action is unknown, it is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by cholinesterase. If this proposed mechanism is correct, rivastigmine's effect may lessen as the disease process advances and fewer cholinergic neurons remain functionally intact.

Rivastigmine Absorption

No information avaliable

Rivastigmine side effects and Toxicity

No information avaliable

Rivastigmine Patient Information

Caregivers should be advised of the high incidence of nausea and vomiting associated with the use of the drug along with the possibility of anorexia and weight loss. Caregivers should be encouraged to monitor for these adverse events and inform the physician if they occur. It is critical to inform caregivers that if therapy has been interrupted for more than several days, the next dose should not be administered until they have discussed this with the physician.

Rivastigmine Organisms Affected

Humans and other mammals